Here, we provided the evidence that isorhamnetin antagonized the effect induced by rosiglitazone and prevented metabolic dysfunction in both diet-induced and leptin-deficient obese mice, thereby identifying isorhamnetin as a novel natural PPARγ antagonist and a potential treatment option for metabolic disorders associated with obesity. The gene discussed is PPARG; the disease is obesity disorder.